Patrick Frey, a key figure in the US FDA's implementation of the past two PDUFA reauthorizations, will leave the agency for industry.
Frey, who has been Office of New Drugs chief of staff for two years, is the latest senior official to...
US FDA's Patrick Frey Joins List Of Agency Leadership Departures
Office of New Drug's chief of staff will become Amgen's director of global regulatory policy and R&D.
